Chronix Biomedical
Pioneering new horizons in diagnosing and managing chronic diseases and cancer through innovative DNA-based assays.
Pioneering new horizons in diagnosing and managing chronic diseases and cancer through innovative DNA-based assays.
Chronix Biomedical is a biotechnology startup that aims to revolutionize the diagnosis and management of chronic diseases and cancer through innovative DNA-based assays. Founded in 1997, the company is based in San Jose, California, with research facilities in Germany. Chronix Biomedical's unique technology involves measuring and categorizing circulating nucleic acids—DNA sequences found in the blood that are linked to specific changes in disease and health status. The startup is focused on collaborating with various partners to develop and market its DNA-based assays, which have the potential to significantly impact the management of numerous cancers and other conditions. The company recently secured a $3.31M Venture Round investment on 18 July 2017. The innovative approach and potential impact of Chronix Biomedical's technology make it a compelling investment opportunity within the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $3.31M | - | 18 Jul 2017 | |
| Venture Round | $5.01M | - | 31 Oct 2016 | |
| Venture Round | $3.43M | - | 08 Apr 2014 | |
| Venture Round | $1.42M | 1 |
|
31 Oct 2012 |
| Venture Round | Unknown | 1 |
|
01 Jan 2012 |
No recent news or press coverage available for Chronix Biomedical.
We care about your data, and we'd love to use cookies make your experience better.
